Author Index

Andersen, D.O., Weber, N.D., Wood, S.G., Hughes, B.G., Murray, B.K. and North, J.A., In vitro virucidal activity of selected anthraquinones and anthraquinone derivatives, 185
Andrei, G., see Snoeck, R., 1
Andries, K., Dewindt, B., Snoeks, J., Willebrords, R., Stokbroekx, R. and Lewi, P.J., A comparative test of fifteen compounds against all known human rhinovirus serotypes as a basis for a more rational screening program (Mini-Review), 213
Andries, K., see White, E.L., 255
Ankel, H., see Bader, Th., 341
Araullo-Cruz, T., see Gordon, Y.J., 11
Awan, A.R., see Field, H.J., 29

Bader, Th., Yamada, Y. and Ankel, H., Antiviral activity of the prostanoid clavulone II against vesicular stomatitis virus, 341
Balestra, E., see Del Gobbo, V., 65
Balzarini, J., see Naesens, L., 53
Balzarini, J., see Neyts, J., 41
Balzarini, J., see Palu, G., 115
Bilello, J.A., see Eiseman, J.L., 307
Birch, G.M., see Nassiri, M.R., 135
Bobek, M., see Kaufman, H.E., 225
Bohm, R., see Soike, K.F., 17
Buckheit, Jr., R.W., see White, E.L., 255

Caliò, R., see Del Gobbo, V., 65
Carpendale, M.T.F. and Freeberg, J.K., Ozone inactivates HIV at noncytotoxic concentrations, 279
Ceruzzi, M., see Kmetz, M.E., 173
Cheng, Y.C., see Kaufman, H.E., 225
Chirigos, M.A., see White, E.L., 255
Clausen, H., see Hansen, J.-E.S., 231
Cohen, J.S., Antisense oligodeoxynucleotides as antiviral agents (Mini-Review), 121
Coleman, L.A., see Nassiri, M.R., 135
Colin, J.-N., see Sinet, M., 163
Craig, J.C., Duncan, I.B., Hockley, D., Grief, C., Roberts, N.A. and Mills, J.S., Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase, 295

De Castro, L.M., Kern, E.R., De Clercq, E., Ghaffar, A., Mayer, E.P., Vogt, P.E. and Gangemi, J.D., Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS, 101
De Clercq, E., see De Castro, L.M., 101
De Clercq, E., see Gordon, Y.J., 11
De Clercq, E., see Maudgal, P.C., 93
De Clercq, E., see Naesens, L., 53
De Clercq, E., see Neyts, J., 41
De Clercq, E., see Palu, G., 115
De Clercq, E., see Snoeck, R., 1
Del Gobbo, V., Foli, A., Balestra, E., Villani, N., Marini, S., Perno, C.F. and Caliò, R., Immunomodulatory activity of phosphonylmethoxyethyl adenine (PMEA), a potent anti-HIV nucleoside analogue, on in vivo murine models, 65
Desforges, B., see Sinet, M., 163
Dewindt, B., see Andries, K., 213
Drach, J.C., see Nassiri, M.R., 135
Duncan, I.B., see Craig, J.C., 295
Dutschman, G.E., see Kaufman, H.E., 225

Ebner, J.P., see Hoover, E.A., 77
Eiseman, J.L., Yetter, R.A., Fredrickson, T.N., Shapiro, S.G., MacAuley, C. and Bilello, J.A., Effect of 3'azidothymidine administered in drinking water or by continuous infusion on the development of MAIDS, 307
Erzurum, S., see Gordon, Y.J., 11

Field, H.J., Awan, A.R. and de la Fuente, R., Isolation of equine herpesvirus-1 mutants in the presence of (*S*)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine: demonstration of resistance in vitro and in vivo, 29
Foli, A., see Del Gobbo, V., 65
Fredrickson, T.N., see Eiseman, J.L., 307
Freeberg, J.K., see Carpendale, M.T.F., 279
de la Fuente, R., see Field, H.J., 29
Fukuma, M., Seto, Y. and Yamase, T., In vitro antiviral activity of polyoxotungstate (PM-19) and other polyoxometalates against herpes simplex virus, 327

Gangemi, J.D., see De Castro, L.M., 101
Germany, J.M., see White, E.L., 255
Ghaffar, A., see De Castro, L.M., 101
Gordon, Y.J., Romanowski, E., Araullo-Cruz, T., Seaberg, L., Erzurum, S., Tolmam, R. and De Clercq, E., Inhibitory effect of (*S*)-HPMPC, (*S*)-HPMPA, and 2'-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro, 11
Grief, C., see Craig, J.C., 295

Hansen, J.-E.S., Nielsen, C., Clausen, H., Mathiesen, L.R. and Nielsen, J.O., Effect of anti-carbohydrate antibodies on HIV infection in a monocytic cell line (U937), 231
Hitchcock, M.J.M., see Soike, K.F., 17
Hockley, D., see Craig, J.C., 295
Holliday, J. and Williams, M.V., Inhibition of herpes simplex virus types 1 and 2 replication in vitro by mercurithio analogs of deoxyuridine, 197
Hoover, E.A., Ebner, J.P., Zeidner, N.S. and Mullins, J.I., Early therapy of feline leukemia virus infection (FeLV-FAIDS) with 9-(2-phosphonylmethoxyethyl)adenine (PMEA), 77
Huang, J.-L., see Soike, K.F., 17
Hudson, J.L., see Nassiri, M.R., 135
Hughes, B.G., see Andersen, D.O., 185

Janssen, P.A.J., see White, E.L., 255

Kaufman, H.E., Varnell, E.D., Cheng, Y.C., Bobek, M., Thompson, H.W. and Dutschman, G.E., Suppression of ocular herpes recurrences by a thymidine kinase inhibitor in squirrel monkeys, 225
Kern, E.R., see De Castro, L.M., 101
Kmetz, M.E., Ceruzzi, M. and Schwartz, J., Vmw65 phosphorothioate oligonucleotides inhibit HSV KOS replication and Vmw65 protein synthesis, 173
Kunita, N., see Otake, T., 241
Kurimura, T., see Otake, T., 241

Launay, O., see Sinet, M., 163
Lewi, P.J., see Andries, K., 213

MacAuley, C., see Eiseman, J.L., 307
Marini, S., see Del Gobbo, V., 65
Martin, J.C., see Soike, K.F., 17
Mathiesen, L.R., see Hansen, J.-E.S., 231
Maudgal, P.C. and De Clercq, E., Effects of phosphonylmethoxyyalkyl-purine and -pyrimidine derivatives on TK+ and TK− HSV-1 keratitis in rabbits, 93
Mayer, E.P., see De Castro, L.M., 101
Mills, J.S., see Craig, J.C., 295
Miyano, K., see Otake, T., 241
Mori, H., see Otake, T., 241
Morimoto, M., see Otake, T., 241
Mullins, J.I., see Hoover, E.A., 77
Murray, B.K., see Andersen, D.O., 185

Naesens, L., Balzarini, J. and De Clercq, E., Single-dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo, 53
Nakashima, H., see Otake, T., 241
Nassiri, M.R., Turk, S.R., Birch, G.M., Coleman, L.A., Hudson, J.L., Pudlo, J.S., Townsend, L.B. and Drach, J.C., Activity of acyclic halogenated tubercidin analogs against human cytomegalovirus and in uninfected cells, 135
Neyts, J., Snoeck, R., Balzarini, J. and De Clercq, E., Particular characteristics of the anti-human cytomegalovirus activity of (*S*)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro, 41
Neyts, J., see Snoeck, R., 1
Nicholas, J.A., see Rubino, K.L., 265
Nielsen, C., see Hansen, J.-E.S., 231
Nielsen, J.O., see Hansen, J.-E.S., 231
Nokta, M.A., see Shafik, H.M., 205
North, J.A., see Andersen, D.O., 185

Otake, T., Miyano, K., Mori, H., Morimoto, M., Ueba, N., Kunita, N., Nakashima, H. and Kurimura, T., Anti-HIV-1 activity of sulfated amphotericin B in vitro, 241

Palu, G., Stefanelli, S., Rassu, M., Parolin, C., Balzarini, J. and De Clercq, E., Cellular uptake of phosphonylmethoxyalkylpurine derivatives (Short Communication), 115
Pancheva, S.N., Potentiating effect of ribavirin on the anti-herpes activity of acyclovir, 151
Parolin, C., see Palu, G., 115
Pauwels, R., see White, E.L., 255
Perno, C.F., see Del Gobbo, V., 65
Pocidalo, J.-J., see Sinet, M., 163
Pollard, R.B., see Shafik, H.M., 205
Pudlo, J.S., see Nassiri, M.R., 135

Rassu, M., see Palu, G., 115
Roberts, N.A., see Craig, J.C., 295
Romanowski, E., see Gordon, Y.J., 11
Ross, L.J., see White, E.L., 255
Rubino, K.L., Tarpley, W.G. and Nicholas, J.A., Effects of a soluble CD4 and CD4-Pseudomonas exotoxin A chimeric protein on human peripheral blood lymphocytes: lymphocyte activation and anti-HIV activity in vitro, 265

Schols, D., see Snoeck, R., 1
Schwartz, J., see Kmetz, M.E., 173
Seaberg, L., see Gordon, Y.J., 11
Seto, Y., see Fukuma, M., 327
Shafik, H.M., Nokta, M.A. and Pollard, R.B., Recombinant human interferon beta ser protects against zidovudine-induced genetic damage in AIDS patients, 205
Shannon, W.M., see White, E.L., 255

Shapiro, S.G., see Eiseman, J.L., 307
Sinet, M., Desforges, B., Launay, 0., Colin, J.-N. and Pocidalo, J.-J., Factors influencing zidovudine efficacy when administered at early stages of Friend virus infection in mice, 163
Snoeck, R., Schols, D., Andrei, G., Neyts, J. and De Clercq, E., Antiviral activity of anti-cytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique, 1
Snoeck, R., see Neyts, J., 41
Snoeks, J., see Andries, K., 213
Soike, K.F., Huang, J.-L., Zhang, J.-Y., Bohm, R., Hitchcock, M.J.M. and Martin, J.C., Evaluation of infrequent dosing regimens with (*S*)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (*S*-HPMPC) on simian varicella infection in monkeys, 17
Stefanelli, S., see Palu, G., 115
Stokbroekx, R., see Andries, K., 213

Tarpley, W.G., see Rubino, K.L., 265
Thompson, H.W., see Kaufman, H.E., 225
Tolmam, R., see Gordon, Y.J., 11
Townsend, L.B., see Nassiri, M.R., 135
Turk, S.R., see Nassiri, M.R., 135

Ueba, N., see Otake, T., 241

Varnell, E.D., see Kaufman, H.E., 225
Villani, N., see Del Gobbo, V., 65
Vogt, P.E., see De Castro, L.M., 101

Weber, N.D., see Andersen, D.O., 185
White, E.L., Buckheit, Jr., R.W., Ross, L.J., Germany, J.M., Andries, K., Pauwels, R., Janssen, P.A.J., Shannon, W.M. and Chirigos, M.A., A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates, 255
Willebrords, R., see Andries, K., 213
Williams, M.V., see Holliday, J., 197
Wood, S.G., see Andersen, D.O., 185

Yamada, Y., see Bader, Th., 341
Yamase, T., see Fukuma, M., 327
Yetter, R.A., see Eiseman, J.L., 307

Zeidner, N.S., see Hoover, E.A., 77
Zhang, J.-Y., see Soike, K.F., 17

Subject Index

AIDS, Human immunodeficiency virus type 1 (HIV-1), Sulfated amphotericin B, Amphotericin B methyl ester, 243
AIDS, Soluble CD4, sCD4-183, sCD4-PE40, HIV, *Pseudomonas* exotoxin A, 267
AIDS, ZDV, Interferon beta, Chromosomal damage, 205
AZT, Animal model of HIV infection, Friend virus, Chemoprophylaxis, 163
Acyclovir, Ribavirin, Combination chemotherapy, HSV-1, PRV, Keratitis, 151
Adenovirus, (*S*)-HPMPC, (*S*)-HPMPA, 2′-**nor-cyclic GMP, 11**
Amphotericin B methyl ester, Human immunodeficiency virus type 1 (HIV-1), Sulfated amphotericin B, AIDS, 243
Animal model of HIV infection, AZT, Friend virus, Chemoprophylaxis, 163
Anthraquinone, Hypericin, Emodin, Virucidal, Tween-80, 185
Antibody-dependent enhancement, HIV, U937, Neutralization, Carbohydrate, 231
Antiherpetic agent, Polyoxometalate, PM-19, Keggin-type structure, 327
Antisense, Drug development, Oligonucleotide, Translation arrest, Transcription arrest, 121
Antiviral therapy, Azidothymidine, Zidovudine, MAIDS, LP-BM5, MuLV, 307
Azidothymidine, Zidovudine, MAIDS, Antiviral therapy, LP-BM5, MuLV, 307

BVDU, HSV-1 keratitis, TK− HSV-1, HPMPA, HPMPC, PMEA, Phosphonylmethoxyalkyl derivative, 93

Carbohydrate, HIV, U937, Neutralization, Antibody-dependent enhancement, 231
Cellular uptake, HPMPA, PMEA, Endocytosis, Nucleoside transport, 115
Chemoprophylaxis, AZT, Animal model of HIV infection, Friend virus, 163
Chemotherapy, Equine herpesvirus-1, EHV-1, Resistance, Phosphonyl, Nucleoside analog, 29
Chromosomal damage, ZDV, Interferon beta, AIDS, 205
Clavulone, Vesicular stomatitis virus, Prostaglandin, 341
Combination chemotherapy, Acyclovir, Ribavirin, HSV-1, PRV, Keratitis, 151
Cytomegalovirus, HPMPC, DNA integrity, 41
Cytomegalovirus, Herpes, 7-Deaza adenosine, Pyrrolopyrimidine, Nucleoside, 135
7-Deaza adenosine, Cytomegalovirus, Herpes, Pyrrolopyrimidine, Nucleoside, 135

DNA hybridization, Human cytomegalovirus, Flow cytometry, 1
DNA integrity, Cytomegalovirus, HPMPC, 41
Dendritic keratitis, Herpes simplex virus, Recurrent ocular herpetic disease, Thymidine kinase, Virus inhibitor, 225
Drug development, Antisense, Oligonucleotide, Translation arrest, Transcription arrest, 121
dUTPase, Herpes simplex virus, Mercurithiodeoxyuridine analog, 197

Emodin, Anthraquinone, Hypericin, Virucidal, Tween-80, 185
Endocytosis, HPMPA, PMEA, Cellular uptake, Nucleoside transport, 115
Equine herpesvirus-1, EHV-1, Resistance, Phosphonyl, Nucleoside analog, Chemotherapy, 29

FeLV-FAIDS, Feline leukemia virus, 9-(2-Phosphonylmethoxyethyl)adenine (PMEA), Immunodeficiency, Retrovirus, 78
Feline leukemia virus, 9-(2-Phosphonylmethoxyethyl)adenine (PMEA), Immunodeficiency, Retrovirus, FeLV-FAIDS, 78
Flow cytometry, Human cytomegalovirus, DNA hybridization, 1
Friend virus, AZT, Animal model of HIV infection, Chemoprophylaxis, 163

HIV, Human immunodeficiency virus, Moloney murine sarcoma virus, MSV, Single dose administration, 53
HIV, Ozone, Noncytotoxic, Virus inhibitor, 279
HIV, Proteinase, Inhibitor, 295
HIV, Soluble CD4, sCD4-183, sCD4-PE40, AIDS, *Pseudomonas* exotoxin A, 265
HIV, U937, Neutralization, Antibody-dependent enhancement, Carbohydrate, 231
HIV-1, TIBO, HIV-2, Reverse transcriptase, Novel RNA template, 255
HIV-2, TIBO, HIV-1, Reverse transcriptase, Novel RNA template, 255
HPMPA, HSV-1 keratitis, TK− HSV-1, BVDU, HPMPC, PMEA, Phosphonylmethoxyalkyl derivative, 93
HPMPA, PMEA, Cellular uptake, Endocytosis, Nucleoside transport, 115

HPMPC therapy, Murine acquired immunodeficiency syndrome, MAIDS, Opportunistic infection, PMEA therapy, 102
HPMPC, Cytomegalovirus, DNA integrity, 41
HPMPC, HSV-1 keratitis, TK− HSV-1, BVDU, HPMPA, PMEA, Phosphonylmethoxyalkyl derivative, 93
HPMPC, Simian varicella virus, Monkey, 17
HSV-1 keratitis, TK− HSV-1, BVDU, HPMPA, HPMPC, PMEA, Phosphonylmethoxyalkyl derivative, 93
HSV-1, Acyclovir, Ribavirin, Combination chemotherapy, PRV, Keratitis, 151
Herpes simplex virus, dUTPase, Mercurithio-deoxyuridine analog, 197
Herpes simplex virus, Dendritic keratitis, Recurrent ocular herpetic disease, Thymidine kinase, Virus inhibitor, 225
Herpes, Cytomegalovirus, 7-Deaza adenosine, Pyrrolopyrimidine, Nucleoside, 135
Human cytomegalovirus, DNA hybridization, Flow cytometry, 1
Human immunodeficiency virus, HIV, Moloney murine sarcoma virus, MSV, Single dose administration, 53
Human immunodeficiency virus type 1 (HIV-1), Sulfated amphotericin B, Amphotericin B methyl ester, AIDS, 243
Hypericin, Anthraquinone, Emodin, Virucidal, Tween-80, 185

Immunodeficiency, Feline leukemia virus, 9-(2-Phosphonylmethoxyethyl)adenine (PMEA), Retrovirus, FeLV-FAIDS, 78
Inhibitor, HIV, Proteinase, 295
Interferon, Nucleoside analog, 9-(2-phosphonylmethoxyethyl)adenine, NK cytotoxicity, Interleukin-1, Interleukin-2, 65
Interferon beta, ZDV, Chromosomal damage, AIDS, 205
Interleukin-1, Nucleoside analog, 9-(2-phosphonylmethoxyethyl)adenine, NK cytotoxicity, Interferon, Interleukin-2, 65
Interleukin-2, Nucleoside analog, 9-(2-phosphonylmethoxyethyl)adenine, NK cytotoxicity, Interferon, Interleukin-1, 65

Keratitis, Acyclovir, Ribavirin, Combination chemotherapy, HSV-1, PRV, 151
Keggin-type structure, Polyoxometalate, PM-19, Antiherpetic agent, 327

LP-BM5, Azidothymidine, Zidovudine, MAIDS, Antiviral therapy, MuLV, 307

MAIDS, Azidothymidine, Zidovudine, Antiviral therapy, LP-BM5, MuLV, 307
MAIDS, Murine acquired immunodeficiency syndrome, Opportunistic infection, HPMPC therapy, PMEA therapy, 102
MSV, Human immunodeficiency virus, HIV, Moloney murine sarcoma virus, Single dose administration, 53
Mercurithio-deoxyuridine analog, Herpes simplex virus, dUTPase, 197
Moloney murine sarcoma virus, Human immunodeficiency virus, HIV, MSV, Single dose administration, 53
Monkey, Simian varicella virus, HPMPC, 17
MuLV, Azidothymidine, Zidovudine, MAIDS, Antiviral therapy, LP-BM5, 307
Murine acquired immunodeficiency syndrome, MAIDS, Opportunistic infection, HPMPC therapy, PMEA therapy, 102

NK cytotoxicity, Nucleoside analog, 9-(2-phosphonylmethoxyethyl)adenine, Interferon, Interleukin-1, Interleukin-2, 65
Neutralization, HIV, U937, Antibody-dependent enhancement, Carbohydrate, 231
Noncytotoxic, HIV, Ozone, Virus inhibitor, 279
Novel RNA template, TIBO, HIV-1, HIV-2, Reverse transcriptase, 255
Nucleoside analog, Equine herpesvirus-1, EHV-1, Resistance, Phosphonyl, Chemotherapy, 29
Nucleoside analog, 9-(2-phosphonylmethoxyethyl)adenine, NK cytotoxicity, Interferon, Interleukin-1, Interleukin-2, 65
Nucleoside transport, HPMPA, PMEA, Cellular uptake, Endocytosis, 115
Nucleoside, Cytomegalovirus, Herpes, 7-Deaza adenosine, Pyrrolopyrimidine, 135

Oligodeoxynucleotide, Phosphorothioate modification, Protein synthesis inhibition, Replication inhibition, 173
Oligonucleotide, Antisense, Drug development, Translation arrest, Transcription arrest, 121
Opportunistic infection, Murine acquired immunodeficiency syndrome, MAIDS, HPMPC therapy, PMEA therapy, 102
Ozone, HIV, Noncytotoxic, Virus inhibitor, 279

9-(2-Phosphonylmethoxyethyl)adenine (PMEA), Feline leukemia virus, Immunodeficiency, Retrovirus, FeLV-FAIDS, 78
9-(2-phosphonylmethoxyethyl)adenine, Nucleoside analog, NK cytotoxicity, Interferon, Interleukin-1, Interleukin-2, 65

PM-19, Polyoxometalate, Keggin-type structure, Antiherpetic agent, 327

PMEA therapy, Murine acquired immunodeficiency syndrome, MAIDS, Opportunistic infection, HPMPC therapy, 102
PMEA, HPMPA, Cellular uptake, Endocytosis, Nucleoside transport, 115
PMEA, HSV-1 keratitis, TK− HSV-1, BVDU, HPMPA, HPMPC, Phosphonylmethoxyalkyl derivative, 93
PRV, Acyclovir, Ribavirin, Combination chemotherapy, HSV-1, Keratitis, 151
Phosphonyl, Equine herpesvirus-1, EHV-1, Resistance, Nucleoside analog, Chemotherapy, 29
Phosphonylmethoxyalkyl derivative, HSV-1 keratitis, TK− HSV-1, BVDU, HPMPA, HPMPC, PMEA, 93
Phosphorothioate modification, Oligodeoxynucleotide, Protein synthesis inhibition, Replication inhibition, 173
Polyoxometalate, PM-19, Keggin-type structure, Antiherpetic agent, 327
Prostaglandin, Vesicular stomatitis virus, Clavulone, 341
Protein synthesis inhibition, Phosphorothioate modification, Oligodeoxynucleotide, Replication inhibition, 173
Proteinase, HIV, Inhibitor, 295
Pseudomonas exotoxin A, Soluble CD4, sCD4-183, sCD4-PE40, AIDS, HIV, 265
Pyrrolopyrimidine, Cytomegalovirus, Herpes, 7-Deaza adenosine, Nucleoside, 135

Rational screening program, Rhinovirus, Screening, antiviral, 213
Recurrent ocular herpetic disease, Dendritic keratitis, Herpes simplex virus, Thymidine kinase, Virus inhibitor, 225
Replication inhibition, Phosphorothioate modification, Oligodeoxynucleotide, Protein synthesis inhibition, 173
Resistance, Equine herpesvirus-1, EHV-1, Phosphonyl, Nucleoside analog, Chemotherapy, 29
Retrovirus, Feline leukemia virus, 9-(2-Phosphonylmethoxyethyl)adenine (PMEA), Immunodeficiency, FeLV-FAIDS, 78
Reverse transcriptase, TIBO, HIV-1, HIV-2, Novel RNA template, 255
Rhinovirus, Rational screening program, Screening, antiviral, 213
Ribavirin, Acyclovir, Combination chemotherapy, HSV-1, PRV, Keratitis, 151

Screening, antiviral, Rational screening program, Rhinovirus, 213
(*S*)-HPMPA, 2′-nor-cyclic GMP, (*S*)-HPMPC, Adenovirus, 11
(*S*)-HPMPC, (*S*)-HPMPA, 2′-nor-cyclic GMP, Adenovirus, 11
sCD4-183, Soluble CD4, sCD4-PE40, AIDS, HIV, *Pseudomonas* exotoxin A, 265
sCD4-PE40, Soluble CD4, sCD4-183, AIDS, HIV, *Pseudomonas* exotoxin A, 265
Simian varicella virus, HPMPC, Monkey, 17
Single dose administration, Human immunodeficiency virus, HIV, Moloney murine sarcoma virus, MSV, 53
Soluble CD4, sCD4-183, sCD4-PE40, AIDS, HIV, *Pseudomonas* exotoxin A, 265
Sulfated amphotericin B, Human immunodeficiency virus type 1 (HIV-1), Amphotericin B methyl ester, AIDS, 243

TIBO, HIV-1, HIV-2, Reverse transcriptase, Novel RNA template, 255
TK− HSV-1, HSV-1 keratitis, BVDU, HPMPA, HPMPC, PMEA, Phosphonylmethoxyalkyl derivative, 93
Thymidine kinase, Dendritic keratitis, Herpes simplex virus, Recurrent ocular herpetic disease, Virus inhibitor, 225
Transcription arrest, Antisense, Drug development, Oligonucleotide, Translation arrest, 121
Translation arrest, Antisense, Drug development, Oligonucleotide, Transcription arrest, 121
Tween-80, Anthraquinone, Hypericin, Emodin, Virucidal, 185

U937, HIV, Neutralization, Antibody-dependent enhancement, Carbohydrate, 231

Vesicular stomatitis virus, Prostaglandin, Clavulone, 341
Virucidal, Anthraquinone, Hypericin, Emodin, Tween-80, 185
Virus inhibitor, Dendritic keratitis, Herpes simplex virus, Recurrent ocular herpetic disease, Thymidine kinase, 225
Virus inhibitor, HIV, Ozone, Noncytotoxic, 279

ZDV, Interferon beta, Chromosomal damage, AIDS, 205
Zidovudine, Azidothymidine, MAIDS, Antiviral therapy, LP-BM5, MuLV, 307